ClinicalTrials.gg
WithdrawnNCT04174677Updated Jun 21, 2024

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

A Phase 2 interventional study of Inebilizumab and VIB4920 in Highly Sensitized Patients on Waiting List for Kidney Transplantation, sponsored by Amgen. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Amgen · Phase 2, Interventional, and Prevention

Why this study was withdrawn
Stopped due to no enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Viela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the combination as part of a multi-center study in highly sensitized patients on the deceased donor waiting list for kidney transplantation. Eligible subjects will be randomized to one of three treatment arms, administered the investigational products as an intervention and subsequently followed for safety.

Read the detailed description

Study acquired from Horizon in 2024.

02

Conditions studied

  • Highly Sensitized Patients on Waiting List for Kidney Transplantation

Keywords

  • cPRA, HLA antibodies, kidney transplantation
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with ESRD who are maintained on hemodialysis.
  2. Subjects awaiting first or second kidney transplantation from a deceased donor.
  3. Subjects with cPRA 98 100% at Screening Visit 1, calculated using antibodies with titer ≥ 1:16 and/or MFI value ≥ 1400, verified by the central laboratory.
  4. Subjects with stable anti-HLA antibody titers (a difference of \< 2 titers versus the average titer of antibodies compared to the screening sample) based on 2 legacy samples drawn within 6 to 12 months prior to Screening Visit 1, verified by the central laboratory.

Exclusion criteria

Exclusion Criteria:

  1. Subjects awaiting kidney transplantation from a living donor.
  2. Subjects who have previously undergone desensitization with plasmapheresis/plasma exchange, IVIG, rituximab, imlifidase, tocilizumab or a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib, others) within 12 months prior to randomization.
  3. Candidates for a second kidney allograft if the first allograft was lost within 12 months prior to screening.
  4. Subjects who have experienced a sensitizing event (eg, pregnancy, blood transfusion) within 6 months prior to screening.
  5. Recipients of a prior non-kidney organ transplant or stem cell transplant.
  6. Subjects treated with systemic drug therapy for more than a total of 2 weeks within 12 months prior to ICF signature (treatment with \< 10 mg/day PO prednisone or equivalent for less than a total of 2 weeks during the 4 weeks prior to screening is allowed).
  7. Subjects who have undergone lympho-depleting therapy (eg, Thymoglobulin, alemtuzumab) within 12 months prior to randomization.
  8. Subjects with known immunodeficiency.
  9. Subjects with known disorders, or history of arterial or venous thromboembolism unrelated to hemodialysis access procedures.
  10. Subjects with history of prothrombotic status (including but not limited to congenital or inherited deficiency of antithrombin III, protein C, protein S), or confirmed diagnosis of catastrophic antiphospholipid syndrome.
  11. Subjects requiring treatment with antithrombotic drugs (clopidogrel, prasugrel, warfarin, others). Low-dose aspirin treatment (up to 325 mg/day) is allowed.
  12. Major surgery within 12 weeks prior to screening.
  13. Receipt of live (attenuated) vaccine within the 4 weeks prior to screening.
  14. Previous treatment with anti-0L agents.
  15. Use of B-cell depleting therapy (eg, inebilizumab, rituximab, ocrelizumab, obinutuzumab), non-depleting B-cell directed therapy (eg, belimumab), an anti-CD40 agent, belatacept, or abatacept within 1 year prior to enrollment.
  16. Use of anti-interleukin (IL)-6 mAbs (eg, tocilizumab, clazakizumab), C1 esterase inhibitors, or complement inhibitors (eg, eculizumab) or imlifidase within 12 months prior to enrollment.
  17. Use of other drugs at the time of enrollment, or within 30 days or 5 half lives of enrollment, whichever is longer.
  18. Subjects who have had more than one episode of severe infection requiring parenteral antimicrobial treatment within 12 months prior to screening.
  19. Subjects with a history of opportunistic infection within 12 months prior to screening (except for PO candidiasis, vaginal candidiasis, and cutaneous fungal infections).
  20. Subjects who have had more than one episode of herpes zoster within 12 months prior to screening.
  21. Subjects with uncontrolled diabetes mellitus ( ≥ 8.0% at screening).
  22. Subjects who have a positive test for, or have been treated for, , , or (HIV) infection.

    Regarding hepatitis B, positive test for chronic hepatitis B infection at screening, defined as either (1) positive hepatitis B surface antigen (HBsAg) or (2) a positive hepatitis B core antibody (anti-HBcAb)

  23. History of or active tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening, unless previously treated for latent TB. Subjects with an indeterminate QuantiFERON®-TB Gold test result can repeat the test, but if the repeat test is also indeterminate, they are excluded.
  24. History of cancer, except as follows:

    1. In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to screening; or
    2. Cutaneous basal cell carcinoma treated with apparent success with curative therapy.
  25. Any severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder that could impact the evaluation of safety and efficacy assessments or affect the subject's ability to participate in the study or the subject's safety.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Inebilzumab Treatment

    Infusion of Inebilizumab

    Drug: Inebilizumab

  • Experimental
    VIB4920 Treatment

    Infusion of VIB4920

    Drug: VIB4920

  • Experimental
    Inebilzumab+VIB4920 Treatment

    Infusion of Inebilizumab and VIB4920

    Drug: Inebilzumab+VIB4920

Interventions

  • Infusion of Inebilizumab

  • Infusion of VIB4920

  • DrugInebilzumab+VIB4920

    Infusion of Inebilizumab and VIB4920

06

What researchers measure

Primary outcomes

  1. Number of subjects with safety events (treatment-emergent adverse events, treatment-emergent serious adverse events, or treatment-emergent adverse events of special interest) during the course of the study

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Anti-drug antibodies (ADA) of inebilizumab and VIB4920

    The ADA incidence rate will be summarized, where the incidence is the proportion of the subjects with ADA positive post-baseline only or boosted their pre existing ADA during the study period.

    Time frame: Through study completion, an average of 1 year

  2. Maximum observed concentration of inebilizumab and VIB4920

    Pharmacokinetic profile

    Time frame: Treatment phase of study (Day 1 of treatment to Day 197)

  3. Area under the concentration-time curve of inebilizumab and VIB4920

    Pharmacokinetic profile

    Time frame: Treatment phase of study (Day 1 of treatment to Day 197)

  4. Total systemic clearance of inebilizumab and VIB4920

    Pharmacokinetic profile

    Time frame: Treatment phase of study (Day 1 of treatment to Day 197)

Other outcomes

  1. Proportion of subjects who achieve at least a 1-, 2-, 3-, or 4-titer reduction in anti-HLA antibody strength in at least 25% of antibodies present before treatment versus any post baseline visit

    Time frame: Day 1 through study completion, an average of 1 year

07

Study locations

2 sites
  • Reserach Site California
    San Diego, California 92123, United States
  • Pennsylvania Reserach Site
    Bethlehem, Pennsylvania 18017, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Dec 2021, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 22, 2019
StartActual
Dec 27, 2019
Primary completionEst.
Dec 2021
CompletionEst.
Apr 2022
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04174677
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Dec 27, 2019
Primary completion
Dec 2021 (estimated)
Completion
Apr 2022 (estimated)
Last update
Jun 21, 2024

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inebilizumab · Dazodalibep

Start the discussion